10-Q: Relmada Therapeutics Q1 2026: Pipeline Advances, Cash Position Strengthens

Relmada Therapeutics reports significant progress in its clinical pipeline with NDV-01 and sepranolone, bolstered by a substantial capital raise, while navigating operational expenses.

Summary

• Relmada Therapeutics filed its Form 10-Q for the quarterly period ended March 31, 2026.
• The company reported a net loss of $19,051,956 for the quarter, compared to $17,559,465 in the same period last year.
• Research and development expenses decreased to $8,087,845 from $11,951,023, primarily due to winding down older studies and the acquisition/licensing of new candidates in the prior year.
• General and administrative expenses increased significantly to $11,373,909 from $6,267,412, driven by increased compensation and consulting services.
• The company's cash and cash equivalents increased substantially to $9,776,400 from $3,496,540, supported by a significant capital raise.
• Short-term investments grew to $224,186,743 from $89,509,710.
• The company has a strong cash position, with management believing it has sufficient funds to operate for at least 12 months.
• Key development programs include NDV-01 for non-muscle invasive bladder cancer (NMIBC) and sepranolone for Prader-Willi Syndrome (PWS) and Tourette Syndrome (TS).
• The company expects to initiate Phase 3 programs for NDV-01 and a Phase 2b study for sepranolone in mid-2026.
• The esmethadone (REL-1017) and psilocybin (REL-P11) programs were terminated in July 2025 and May 2025, respectively.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to significant progress in clinical development, strong data for NDV-01 and sepranolone, and a substantially strengthened cash position following a large capital raise, despite ongoing operational losses.

Positives

• Substantial increase in cash and cash equivalents to $9,776,400 and short-term investments to $224,186,743, indicating a strong financial position.
• Successful completion of a private placement raising approximately $150 million in March 2026, significantly bolstering liquidity.
• Positive 12-month safety and efficacy data for NDV-01 in high-risk NMIBC, with no new safety signals and a 63% treatment-related adverse event rate, mostly mild.
• High efficacy rates for NDV-01 in the Phase 2 study, with a 95% CR rate anytime and 76% at 12 months in the overall population, and 84% at 12 months in the BCG-unresponsive subpopulation.
• FDA alignment on key elements for the planned Phase 3 pivotal program for NDV-01, including study design and endpoints for both high-grade and intermediate-risk NMIBC.
• Positive results from a Phase 2a study of sepranolone in Tourette Syndrome, showing competitive tic reduction (28% YGTSS reduction, p=0.051) and improvements in quality of life, impairment, and premonitory urge.
• Sepranolone demonstrated no off-target CNS or systemic side effects in the TS study and has been well-tolerated in over 335 participants in prior studies.
• Intellectual property portfolio provides potential coverage beyond 2038 for sepranolone and NDV-01, with a provisional patent application for NDV-01 potentially extending coverage to 2047.
• Management believes the company has sufficient funds to maintain operations for at least 12 months from the issuance of the financial statements.

Negatives

• Continued net loss of $19,051,956 for the quarter, consistent with the company's clinical-stage development model.
• Significant increase in general and administrative expenses by $5,106,500, primarily due to higher compensation and consulting costs.
• Research and development expenses, while decreased, still represent a substantial outflow of capital ($8,087,845).
• The company has not generated any revenue and does not anticipate generating revenue for the foreseeable future.
• The esmethadone and psilocybin programs were terminated, indicating past development setbacks.
• Stock-based compensation and stock appreciation rights continue to be significant non-cash expenses.

Risks

• The company is subject to risks common to biotechnology companies, including dependence on collaborative arrangements, development of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulatory requirements.
• There is no assurance that the company's research and development will be successfully completed or that any product will be approved or commercially viable.
• The company has incurred losses and negative cash flows from operations since inception and expects to incur additional losses.
• Future financing may be required through public or private sales of equity or debt securities, bank loans, or strategic collaborations, and there is no guarantee such financing will be available on favorable terms or at all.
• The company's stock price could be materially and adversely affected by the occurrence of risks outlined in the report.
• The company is currently not aware of any legal proceedings or potential claims that would likely have a material adverse effect, but litigation is subject to inherent uncertainties.

Future Outlook

Relmada Therapeutics anticipates initiating Phase 3 programs for NDV-01 in two indications (high-risk, 2nd line BCG-unresponsive NMIBC and intermediate risk in the adjuvant setting) by mid-2026. Additionally, a Phase 2b study for sepranolone in Prader-Willi Syndrome is also expected to commence mid-2026. The company expects to receive initial 3-month data from the Phase 3 high-risk NMIBC trial by year-end 2026. Management believes current cash and investments are sufficient for at least 12 months, with future financing to be evaluated for subsequent trials.

Management Comments

• Management believes that the Company's existing cash and cash equivalents and short-term investments will enable it to fund operating expenses and capital expenditure requirements for at least 12 months from the issuance of these unaudited condensed consolidated financial statements.
• Beyond that point management will evaluate the size and scope of any subsequent trials that will affect the timing of additional financing through public or private sales of equity or debt securities or from bank or other loans or through strategic collaboration and/or licensing agreements.
• Any such expenditures related to any subsequent clinical trials will not be incurred until such additional financing is raised.
• As a result, the Company concluded the Company has sufficient funds to maintain operations for at least 12 months from the issuance of these unaudited condensed consolidated financial statements.

Industry Context

StockSavvy.ai notes that Relmada Therapeutics' strategic shift towards acquiring new development candidates, exemplified by the licensing of NDV-01 and acquisition of sepranolone, aligns with industry trends of pipeline diversification and risk mitigation in the competitive biotechnology sector. The company's focus on NMIBC and neurosteroid-based therapies targets significant unmet medical needs, positioning it within key growth areas of the pharmaceutical market.

Comparison to Industry Standards

• The NDV-01 program's approach to treating NMIBC, particularly its sustained-release formulation, aims to improve upon existing intravesical chemotherapy regimens. While BCG shortages have driven interest in alternatives, the efficacy and tolerability data presented for NDV-01 (95% CR anytime, 76% at 12 months) appear competitive, though direct comparisons to industry-standard treatments like BCG require further Phase 3 validation.
• The sepranolone program for Tourette Syndrome shows a 28% reduction in YGTSS scores, which is a meaningful improvement. Industry benchmarks for TS treatment efficacy vary, but this result is promising and comparable to some established therapies, especially considering the lack of CNS side effects.
• The company's net loss of $19 million for the quarter is substantial but not unusual for a clinical-stage biotechnology company. Many companies in this sector operate at a loss for extended periods, funding operations through equity raises, as Relmada has done with its recent $150 million private placement.

Legal Proceedings

• The Company is currently not aware of any legal proceedings or potential claims against it whose outcome would be likely, individually or in the aggregate, to have a material adverse effect on the Company's business, financial condition, operating results, or cash flows.

Stakeholder Impact

• Shareholders: The substantial capital raise and positive clinical data for key pipeline assets are positive for shareholders, potentially increasing future value. However, the ongoing net losses and need for future financing present risks.
• Employees: Increased G&A expenses suggest potential growth in headcount, which could benefit employees through new opportunities. Stock-based compensation and SARs continue to be a significant component of employee compensation.
• Creditors: The strong cash position and recent capital raises reduce immediate concerns for creditors regarding the company's ability to meet its obligations.
• Suppliers: Increased manufacturing and drug storage costs for NDV-01 and sepranolone suggest increased activity with suppliers for these programs.

Next Steps

• Initiate Phase 3 programs for NDV-01 in two indications (high-risk, 2nd line BCG-unresponsive NMIBC and intermediate risk in the adjuvant setting) mid-2026.
• Initiate a Phase 2b study of sepranolone in Prader-Willi Syndrome mid-2026.
• File an Investigational New Drug (IND) application with the FDA for NDV-01 to initiate a clinical trial in NMIBC.
• Obtain initial 3-month data from the Phase 3 High-risk, 2nd line BCG-unresponsive NMIBC Trial for NDV-01 by year-end 2026.
• Management will evaluate the size and scope of subsequent trials to determine the timing of additional financing.

Key Dates

Recommendation

Relmada Therapeutics presents a mixed picture. The company has made significant strides in advancing its pipeline with promising clinical data for NDV-01 and sepranolone, and has secured substantial funding through recent capital raises, strengthening its liquidity. However, it continues to incur significant net losses, and its success hinges on the future clinical and regulatory outcomes of its drug candidates. While the progress is encouraging, the inherent risks and long development timelines in the biotech sector warrant a cautious 'hold' recommendation until further de-risking events occur.

Keywords

Relmada Therapeutics, Form 10-Q, Quarterly Report, Biotechnology, Clinical Stage, NDV-01, Sepranolone, NMIBC, Bladder Cancer, Prader-Willi Syndrome, Tourette Syndrome, Drug Development, FDA, Phase 2, Phase 3, Capital Raise, Financial Results